Trials / Completed
CompletedNCT00901719
Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation
Investigating the Interaction of Apelin and Systemic Angiotensin II Peripheral Resistance Vessels and Systemic Haemodynamics in Vivo in Man
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- University of Edinburgh · Academic / Other
- Sex
- All
- Age
- 18 Months – 85 Years
- Healthy volunteers
- Accepted
Summary
The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease. Two of the main actions of apelin are to increase the pumping ability of the heart and cause blood vessels to relax. The investigators wish to assess if these actions are altered in the setting of normal renin-angiotensin activation and increased renin-angiotensin activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apelin | Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml. |
| DRUG | Acetylcholine | Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min |
| DRUG | Sodium nitroprusside | Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min |
| DRUG | Systemic apelin infusion | Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals. |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2009-05-14
- Last updated
- 2010-08-10
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00901719. Inclusion in this directory is not an endorsement.